Following the Commercial Production Determination Sample Clauses

Following the Commercial Production Determination. HITACHI shall manufacture the HITACHI Products for sale to NANOGEN and for sale by HITACHI within Japan, and NANOGEN shall develop and manufacture the NANOGEN Products for sale to HITACHI, in each case in accordance with the Product Specifications. NANOGEN responsibilities related thereto include final analytical performance of [***] CONFIDENTIAL TREATMENT REQUESTED HITACHI Products, all necessary design and development costs for NANOGEN Products, including biochip cartridges, user interface, instrument control and applications and data handling software. Within [***] of the Effective Date, NANOGEN shall assure that the above referenced software is validated in accordance with applicable laws and FDA regulations. NANOGEN and HITACHI shall promptly meet and agree on documentation standards and test criteria that establish conformance to HITACHI's standards and quality approval. If the software does not meet HITACHI's quality standards through demonstrated conformance to the test criteria within the time period to be agreed between the Parties, the Parties shall discuss and agree on a course of action. NANOGEN grants to HITACHI the right to modify NANOGEN's user interface and instrument control software consistent with HITACHI's responsibility for hardware, and all such changes and improvements will be licensed to NANOGEN solely during the term of this Agreement on a fully paid-up, royalty-free basis, worldwide. NANOGEN also grants to HITACHI the right to design unique user interface software for the HITACHI Products sold in Japan. NANOGEN and HITACHI shall grant each other solely during the term of this Agreement a fully paid-up, royalty-free, worldwide license to software improvements developed by either Party for HITACHI Products in the areas of user interface, instrument control, applications and data handling.
AutoNDA by SimpleDocs
Following the Commercial Production Determination. HITACHI shall pay NANOGEN a sales commission on sales of HITACHI Products made by HITACHI in the Japanese market during the term of this Agreement. The initial sales commission shall equal [***] of the estimated average sales price of such HITACHI Products. Such estimated average sales price shall be determined by the Parties at the same time as the prices for HITACHI Products are determined pursuant to [***] CONFIDENTIAL TREATMENT REQUESTED Sections 7.1.2 and 7.1.3, and shall be effective through September 30 of the subject year. Such sales commission shall be calculated on the basis of sales made and invoiced by HITACHI during each calendar quarter, and shall be paid by HITACHI to NANOGEN within forty five (45) days of the close of each calendar quarter. Such commissions shall be paid in U.S. Dollars, with the conversion of Japanese Yen denominated sales proceeds to U.S. Dollars determined based on the U.S. Dollar/Japanese Yen exchange rate in effect at the end of the subject calendar quarter. If in any such year or portion thereof ending with September 30 the total commissions paid are not equal to an agreed minimum commission, HITACHI shall, following the end of such year or portion thereof, pay NANOGEN the difference between the actual commissions paid during such year and that minimum commission amount. That minimum commission for the first year, ending with [***], shall be discussed at the time of the Commercial Production Determination and mutually agreed to by the Parties. The minimum commission for subsequent years shall be negotiated in good faith by the Parties at the same time as the prices for HITACHI Products for such year are determined pursuant to Section7.1.3, based on HITACHI's forecast of HITACHI Products sales in Japan during such year.
Following the Commercial Production Determination. HITACHI and NANOGEN shall use their reasonable best efforts to deliver HITACHI Products and Spare Parts within [***] calendar days after HITACHI's receipt of a purchase order [***] CONFIDENTIAL TREATMENT REQUESTED 1. If a Party's requirements exceed [***] of the quantity last forecast to be ordered in that month pursuant to Section 5.1, the other Party shall use its reasonable best efforts to deliver product within [***] days after such Party's receipt of the other Party's purchase order. A Party's compliance with agreed delivery dates is further conditioned on prompt receipt from the other Party of all necessary shipping information.

Related to Following the Commercial Production Determination

  • DEVELOPMENT OR ASSISTANCE IN DEVELOPMENT OF SPECIFICATIONS REQUIREMENTS/ STATEMENTS OF WORK

  • Independence from Material Breach Determination Except as set forth in Section X.D.1.c, these provisions for payment of Stipulated Penalties shall not affect or otherwise set a standard for OIG’s decision that Xxxxx has materially breached this IA, which decision shall be made at OIG’s discretion and shall be governed by the provisions in Section X.D, below.

  • Termination Notice for Force Majeure Event If a Force Majeure Event subsists for a period of 180 (one hundred and eighty) days or more within a continuous period of 365 (three hundred and sixty five) days, either Party may in its discretion terminate this Agreement by issuing a Termination Notice to the other Party without being liable in any manner whatsoever, save as provided in this Article 34, and upon issue of such Termination Notice, this Agreement shall, notwithstanding anything to the contrary contained herein, stand terminated forthwith; provided that before issuing such Termination Notice, the Party intending to issue the Termination Notice shall inform the other Party of such intention and grant 15 (fifteen) days time to make a representation, and may after the expiry of such 15 (fifteen) days period, whether or not it is in receipt of such representation, in its sole discretion issue the Termination Notice.

  • License Period a. The License is hereby granted in favour of the Licensee for a total period of 15 (fifteen) years from the Commencement Date subject to unless otherwise terminated by Maha-Metro or surrendered by the Successful Bidder/Licensee, in term of provisions of License Agreement. b. The tenure of License Agreement shall commence from the date of handing over of the property business space. c. Tenure of the License Period of any additional space handed over subsequently shall be co- terminus with above period irrespective of date of actual handing over for such additional space. d. There shall be a lock in period of five (05) years from the date of commencement of agreement/ handing over of licensed space. e. Licensee shall have option to exit from the License Agreement immediately after completion of lock in period of 5 (Five) years. For it, Licensee shall have to issue 180 days prior notice to Maha-Metro. Such prior notice intimation can be given after four and half (4 ½) years however option to exit will be available only after five (05) years. f. At no time during the license tenure, the Licensee shall be allowed to surrender partial Licensed Space which has been handed over to the Licensee by Maha-Metro. g. At the end of License period or in the event of termination of this agreement prior to completion of license tenure, for any reason whatsoever, all rights given under this License Agreement shall cease to have effect and the premises shall revert to Maha-Metro, without any obligation to Maha-Metro to pay or adjust any consideration or other payment to the Licensee. h. The tenure shall be inclusive of fitment period as applicable for the tendered space. i. On completion/ termination of License Agreement, the Licensee shall hand over the space with normal wear & tear. The Licensee shall be allowed to remove its assets like temporary structure, furniture, almirahs, air-conditioners, DG sets, equipments, etc. without causing damage to the existing structure. However, the Licensee shall not be allowed to remove any facility, equipment, fixture, etc. which has become an integral part of the development plan of the space. j. At the end of the License Period or sooner determination of this Agreement for any reason whatsoever all rights given under this License Agreement shall cease to have effect and the Licensed Area with all the furniture and fixtures and other assets permanently attached to the Licensed Area shall revert to Maha-Metro without any obligation on part of Maha-Metro to pay or adjust any consideration or other payment to the Licensee. The Licensee voluntarily gives Maha-Metro the right to seal the said Licensed Space(s) and remarket the same as part on its discretion upon Termination of this Agreement. No claim, compensation or damages will be entertained by Maha-Metro on this account.

  • Reasonable Commercial Efforts (a) Subject to the terms and ------------------------------ conditions provided in this Agreement, each party shall use reasonable commercial efforts to take promptly, or cause to be taken, all actions, and to do promptly, or cause to be done, all things necessary, proper or advisable under applicable laws and regulations to consummate and make effective the transactions contemplated hereby, to obtain all necessary waivers, consents and approvals and to effect all necessary registrations and filings, including, without limitation, an appropriate filing of a Notification and Report Form pursuant to the HSR Act with respect to the transactions contemplated hereby, and the filings and consents set forth on Schedule 6.4 hereto (the "Required ------------ -------- Consents") and to remove any injunctions or other impediments or delays, legal -------- or otherwise, in order to consummate and make effective the transactions contemplated by this Agreement for the purpose of securing to the parties hereto the benefits contemplated by this Agreement; provided that notwithstanding -------- anything to the contrary in this Agreement, no party nor any of their Affiliates shall be required to make any disposition, including, without limitation, any disposition of, or any agreement to hold separate, any Subsidiary, asset or business, and no party hereto nor any of their Affiliates shall be required to make any payment of money nor shall any party or its Affiliates be required to comply with any condition or undertaking or take any action which, individually or in the aggregate, would materially adversely affect the economic benefits to such party of the transactions contemplated hereby and the Implementing Agreements, taken as a whole or adversely affect any other business of such party or its Affiliates. (b) Each of the parties hereto shall execute and cause its Subsidiaries to execute on or prior to the Closing Date each Implementing Agreement to which it or they are a party on the terms set forth in the relevant Exhibits hereto. (c) Each of the parties hereto agrees, from time to time, to execute and deliver, or use reasonable commercial efforts to cause to be executed and delivered, such additional instruments, certificates or documents (including bills of sale and assignment and assumption agreements), and take all such actions, reasonably necessary to implement or effectuate the transactions contemplated by this Agreement.

  • Commercialization Efforts The RECIPIENT shall, including whether through its own efforts or the efforts of a licensee under a License Agreement allowed by the terms of this Attachment, use diligent and commercially reasonable efforts to commercialize at least one Commercial Product or Commercial Service or otherwise bring to practical application the Project Results in accordance with the commercial development plan submitted with the Application and including any changes to such commercial development plan in accordance with Section D3.01. For the avoidance of doubt, partnering or licensing activities shall be considered to be efforts to commercialize.

  • Commercial Diligence Pfizer will use Commercially Reasonable Efforts to Commercialize at least [**] in [**], where Pfizer or its designated Affiliates or sublicensees seek and receive Regulatory Approval for such [**]. Pfizer will have no other diligence obligations with respect to the Commercialization of Licensed Products except as otherwise set forth in this Agreement.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • Development Diligence Pfizer will use its Commercially Reasonable Efforts to Develop and seek Regulatory Approval for [ * ] Product [ * ] in the Field [ * ]. Pfizer will [ * ] with respect to the Development or Regulatory Approval of Products under this Agreement.

  • Proposing Integration Activities in the Planning Submission No integration activity described in section 6.3 may be proposed in a CAPS unless the Funder has consented, in writing, to its inclusion pursuant to the process set out in section 6.3(b).

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!